Zobrazeno 1 - 10
of 213
pro vyhledávání: '"Te, An Shu"'
Publikováno v:
Humanis, Vol 26, Iss 1, Pp 68-77 (2022)
This study is a corpus-based analysis that aims to investigate the productivity of the -te and -shu suffixes as agent-forming suffixes in Japanese as well as the structure of noun formation by adding these two suffixes. The theories used in this rese
Externí odkaz:
https://doaj.org/article/1b5503ae8138459a8e8f347c915a2713
Autor:
Makowski, Dominique, Te, An Shu, Neves, Ana, Kirk, Stephanie, Liang, Ngoi Zi, Mavros, Panagiotis, Chen, S.H. Annabel
Publikováno v:
In Acta Psychologica February 2025 252
Autor:
Lévy, André
Publikováno v:
Chinese Literature: Essays, Articles, Reviews (CLEAR), 1981 Jan 01. 3(1), 179-183.
Externí odkaz:
https://www.jstor.org/stable/495352
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wai-Yee, Li
Publikováno v:
Digest of Chinese Studies, 1988 Jan 01, 69-71.
Externí odkaz:
https://www.jstor.org/stable/44291959
Autor:
Pulleyblank, E. G.
Publikováno v:
Revue Bibliographique de Sinologie, 1958 Jan 01. 4, 410-411.
Externí odkaz:
https://www.jstor.org/stable/24594957
Autor:
Makowski, Dominique1,2 (AUTHOR) D.Makowski@sussex.ac.uk, Te, An Shu1 (AUTHOR), Kirk, Stephanie1 (AUTHOR), Liang, Ngoi Zi1 (AUTHOR), Chen, S. H. Annabel1,3,4,5 (AUTHOR)
Publikováno v:
Scientific Reports. 4/22/2023, Vol. 13 Issue 1, p1-11. 11p.
Autor:
Makowski, Dominique1 (AUTHOR) dom.makowski@gmail.com, Te, An Shu1 (AUTHOR) phamttam17@gmail.com, Pham, Tam1 (AUTHOR) lauzenjuen@gmail.com, Lau, Zen Juen1 (AUTHOR), Chen, S. H. Annabel1,2,3,4 (AUTHOR) dom.makowski@gmail.com
Publikováno v:
Entropy. Aug2022, Vol. 24 Issue 8, p1036-N.PAG. 12p.
Autor:
Andre Levy, Sun Shu-yu (Sun Shuyu)
Publikováno v:
Chinese Literature: Essays, Articles, Reviews (CLEAR). 3:179
Publikováno v:
Cancer Research. 75:3065-3065
Lung cancer is the leading cause of cancer-related death. Although molecular targeting therapy (MTT) could benefit patients with EGFR activating mutations, chemotherapy still is the first choice of EGFR wild type patients, MTT failed ones and patient